Immunostimulatory CpG motifs have been implicated as a major contributor to the acute inflammatory response associated with nonviral vectors, most prominently seen after systemic delivery of cationic lipid-plasmid DNA (pDNA) complexes. We have shown previously that complexes containing pDNA vectors that have been largely depleted of CpG motifs have significantly reduced acute toxicity when delivered systemically. However, several CpGs remain in these vectors and the toxicity is not negligible, especially at higher doses of complex. To determine the maximal reduction in the acute toxic response that could be achieved by eliminating CpG signaling, we injected cationic lipid-pDNA complexes into transgenic mice that are deficient in Toll-like receptor 9 (TLR9), which is the receptor that recognizes immunostimulatory CpG motifs. We observed significantly decreased adverse hematological changes and liver damage in TLR9(-/-) mice compared to normal mice and increased survival at higher doses of complex. However, a pronounced loss of lymphocytes and platelets was still observed in the TLR9(-/-) mice at higher doses. We also measured the toxicity in normal mice of systemically delivered complexes containing non-CpG oligonucleotides. Although serum transaminase levels were reduced, a loss of lymphocytes and platelets akin to that seen in the TLR9(-/-) mice was observed. Taken together, these findings suggest that signaling through TLR9 contributes to the majority but not all of the toxic responses associated with systemic delivery of cationic lipid-pDNA complexes.
No abstract is provided for this article.
This has led to the identification of several important roles for Toll receptors in mammals. This unit discusses mammalian Toll receptors (TLR1‐10) that have an essential role in the innate immune recognition of microorganisms. Also discussed are TLR‐mediated signaling pathways and antibodies that are available to detect specific TLRs.
Various cell types, including macrophages, dendritic cells (DCs), neutrophils, natural killer cells, and fibroblasts, express Toll-like receptors (TLRs) that activate the immune system (1, 2). TLRs are type I transmembrane proteins with ectodomains containing leucine-rich repeats that mediate the recognition of pathogen-associated molecular patterns (PAMPs) derived from pathogens, and damage-associated molecular patterns (DAMPs) from dying or injured cells. TLRs harbor transmembrane domains and intracellular Toll–interleukin-1 (IL-1) receptor (TIR) domains in addition to leucine-rich repeat domains, and some adaptor molecules bind to them to activate the downstream signaling pathways. Various organisms express the TLR family, especially mammals, and 13 types of TLRs have been reported. TLR1 to -9 are conserved in both the mouse and human. However, in mice, a retroviral insertion has rendered the TLR10 molecule nonfunctional. TLR11, -12, and -13 do not occur in humans. The active TLRs localize differently. TLR1, -2, -4, -5, -6, and -10 are expressed on the cell surface, whereas TLR3, -7, -8, -9, -11, -12, and -13 are expressed in the endosome (3 , 4). Studies of mice deficient in each TLR have shown that each TLR has a distinct function in terms of PAMP recognition and the immune responses.